Selank: what the studies show

Selank and modified variants

Selank is the synthetic heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, also called TP-7. N-acetyl Selank and N-acetyl Selank amidate are chemically modified variants. The cited studies do not establish these variants' effectiveness or interchangeable delivery.

The anxiety comparison

A Russian study compared Selank in 30 patients with medazepam in 32 patients who had generalized anxiety disorder or neurasthenia. The authors reported similar anxiety-scale effects. PubMed classifies the report as randomized, but the accessible English abstract gives no placebo arm and insufficient detail on blinding, route, or duration.

Similar results against another drug do not prove equal effectiveness without a defined equivalence margin. The comparison also cannot establish long-term freedom from dependence or adverse effects.

Nasal research and safety gaps

A separate rat experiment used intranasal Selank over 14 days and measured maze behavior under stress. That experiment does not establish a human nasal schedule or benzodiazepine combination.

No FDA-approved product was identified. FDA describes unresolved risks for Selank acetate. Placebo-controlled clinical benefit and formulation-specific human safety remain unresolved.